Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for thapsigargin (compound)
Most Correlated Studies
- Cancer cell lines exposed to disulfide bond inhibitors or anoxic conditions
- Mouse embryonic fibroblasts treated with thapsigargin; free and polysome associated RNA
- Fibroblasts from SIAH1/SIAH2 knockouts with low glucose/oxygen, tunicamycin, or thapsigargin
- Cardiomyocytes (mature and progenitors) treated with thapsigargin, tunicamycin or halofuginone
- Neuroblastoma cell line SH-SY5Y treated with thapsigargin, tunicamycin, or atrazine
Most Relevant Literature
- Thapsigargin: key to new host-directed coronavirus antivirals?
- Thapsigargin blocks electromagnetic field-elicited intracellular Ca2+ increase in HEK 293 cells.
- Rh(I)-Catalyzed Allenic Pauson-Khand Reaction to Access the Thapsigargin Core: Influence of Furan an…
- Thapsigargin-From Traditional Medicine to Anticancer Drug.
- Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin.
Most Relevant Clinical Trials
- Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
- Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive G…
- Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
- Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
- Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
